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http://www.biomedcentral.com/1471-2156/15/38RESEARCH ARTICLE Open AccessPSPHL and breast cancer in African American
women: causative gene or population
stratification?
Seth Rummel1, Cayla E Penatzer1, Craig D Shriver2 and Rachel E Ellsworth3*Abstract
Background: Phophoserine phosphatase-like (PSPHL) is expressed at significantly higher levels in breast tumors
from African American women (AAW) compared to Caucasian women (CW). How overexpression of PSPHL
contributes to outcome disparities is unclear, thus, molecular mechanisms driving expression differences between
populations were evaluated.
Results: PCR was used to detect deletion of 30-Kb of chromosome 7p11 including the first three exons of PSPHL
using genomic DNA from AAW (199 with invasive breast cancer, 360 controls) and CW (invasive breast cancer =589,
364 controls). Gene expression levels were evaluated by qRT-PCR using RNA isolated from tumor tissue and blood.
Data were analyzed using chi-square analysis and Mann–Whitney U-tests; P < 0.05 was used to define significance.
Gene expression levels correlated with deletion status: patients homozygous for the deletion had no detectable
expression of PSPHL, while heterozygous had expression levels 2.1-fold lower than those homozygous for retention of
PSPHL. Homozygous deletion of PSPHL was detected in 61% of CW compared to 6% of AAW with invasive breast cancer
(P < 0.0001); genotype frequencies did not differ significantly between AAW with and without breast cancer (P = 0.211).
Conclusions: Thus, deletion of 7p11, which prevents expression of PSPHL, is significantly higher in CW compared to
AAW, suggesting that this 30-kb deletion and subsequent disruption of PSPHL may be a derived trait in Caucasians. The
similar frequency of the deletion allele in AAW with and without invasive breast cancer suggests that this
difference represent population stratification, and does not contribute to cancer disparities.
Keywords: PSPHL, African American, Cancer disparity, Population stratificationBackground
The phosphoserine phosphatase-like (PSPHL [GenBank
AJ001612.1]) gene was identified over a decade ago as a
gene upregulated in fibroblasts from patients with Fanconi
Anemia (FA) [1]. Although the gene shares multiple re-
gions of sequence homology with phosphoserine phosphat-
ase, a 476-bp fragment missing from PSPHL results in an
altered coding region. Microarray analysis of the ocular
disease pterygia identified PSPHL as one of three genes
that could predict disease recurrence; immunohistochemi-
cal analysis revealed PSPHL is expressed at the superficial
epithelium of the primary but not recurrent pterygia, sug-
gesting that decreased PSPHL is correlated with increasing* Correspondence: r.ellsworth@wriwindber.org
3Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement
of Military Medicine, 620 Seventh Street, Windber, PA 15963, USA
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reproduction in any medium, provided the oralterations in the basement membrane [2]. A deletion/in-
sertion (del/ins) polymorphism within the PSPHL gene has
also been associated with susceptibility to bipolar disorder
[3]. Despite these associations with disease states, the func-
tion of PSPHL remains unknown.
Microarray analysis has revealed significantly higher
PSPHL expression levels in a variety of tumor types from
African Americans compared to Caucasians. For example,
studies using gene expression analysis found significantly
higher expression of PSPHL in prostate tumors, the sur-
rounding microenvironment, and in primary cell cultures
from prostate tumors from African American compared to
Caucasian men [4,5]. Higher expression of PSPHL has also
been found in breast tumors, the tumor microenvironment
and non-malignant breast stroma from African American
women (AAW) [6,7]. Expression levels of PSPHL were alsol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Genotype frequencies of the deletion (del)/
insertion (ins) polymorphism of 30 Kb on chromosome
7p11 amongst the four patient groups
Del/Del Ins/Del Ins/Ins P-value
AA case 0.06 (n = 12) 0.35 (n = 70) 0.59 (n = 117)
C case 0.62 (n = 362) 0.34 (n = 202) 0.04 (n = 25) P < 0.0001a
AA controls 0.04 (n = 13) 0.31 (n = 112) 0.65 (n = 235) P = 0.211b
C controls 0.64 (n = 232) 0.34 (n = 123) 0.02 (n = 9) P = 0.336c
AA = African American, C = Caucasian.
aP-value calculated between African American and Caucasians with invasive
breast cancer.
bP-value calculated between African American cases and controls.
cP-value calculated between Caucasian cases and controls.
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from AAW compared to Caucasian women (CW) [8,9].
This detection of significantly higher levels of PSPHL
has been in sex-hormone derived tumors, which have
been shown to have less favorable outcomes in African
American compared to Caucasian patients [10]. Altered
expression of PSPHL in FA suggests that PSPHL may
influence rates of cellular proliferation [1], which may
promote more aggressive tumor biology and less favor-
able outcomes. PSPHL is an 841 bp gene spread over
four exons on chromosome 7p11.2. The promoter and
first three exons of PSPHL are located within a 30 Kb
region that is not represented in the human reference
sequence, thus individuals harboring this deletion would
not express PSPHL. If increased expression of PSPHL
drives pro-tumorigenic properties, this may contributeFigure 1 Graphical representation of expression levels of PHPHL in tu
del/ins = heterozygous, ins/ins = homozygous for insertion variant.to higher mortality rates in AAW. In contrast, baseline
expression of PSPHL is heritable [11], thus higher expres-
sion levels of PSPHL may reflect different minor allele
frequencies in patients of European compared to African
ancestry. To determine whether PSPHL is involved in
tumorigenesis or reflects population stratification, the
association between retention or loss of the 30 Kb
region on chromosome 7p11 and expression levels of
PSPHL were investigated in African American and
Caucasian populations.
Results
Genomic DNA was available from 199 AAW and 589
CW with invasive breast cancer, and 360 AAW and 364
CW controls. Genotypes were successfully generated for
all available specimens. All populations were in Hardy-
Weinberg equilibrium. Genotype frequencies were sig-
nificantly different between AAW and CW with breast
cancer (Table 1) but not between AAW with and with-
out breast cancer. In addition, genotype frequencies
were not significantly different between CW cases and
controls. Deletion (del) allele frequencies were signifi-
cantly lower in AAW with (0.24) and without (0.19) in-
vasive breast cancer compared to those in CW with
invasive breast cancer (0.77) and CW controls (0.81).
Expression levels for PSPHL were generated by qRT-
PCR from 116 tumor specimens (33 AAW and 83 CW)
and 49 blood samples, 13 of which overlapped with the
tumor samples. Patients with the del/del genotype hadmor tissues by genotype. Del/del = homozygous for deletion variant,
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(n = 23). Expression levels in breast tissue (Figure 1) were
2.1-fold higher in patients homozygous for the insertion
allele compared to heterozygotes (P < 0.005), while tissue
from patients expressing one or two copies of PSPHL
were significantly higher than those patients homozygous
for the deletion allele (P < 0.00001). When analyzing blood
RNA, expression of PSPHL was significantly higher in car-
riers of the insertion allele (ins/ins or ins/del) compared to
patients homozygous for the deletion allele (<P < 0.005),
although PSPHL levels did not differ significantly in blood
RNA between heterozygotes (n = 17) and those with the
ins/ins genotype (n = 9), which may be attributable to
small sample size.Table 2 Association between retention or absence of 30 Kb re
by ethnic group
AAW
Del/Del (n = 12) Del/Ins or Ins/Ins (n = 186) P
Age
<50 years 0.33 0.44



























aDOC = dead other causes, DOD = dead of disease, AWD = alive with disease, NED =To determine whether expression of PSPHL was asso-
ciated with aggressive tumor characteristics or survival,
the loss (del/del) or retention (ins/del or ins/ins) of the
30 Kb of chromosome 7p was evaluated within each
population for a number of clinical factors (Table 2).
Although AAW were more likely to be diagnosed at a
younger age, with ER-/HER2-, high-grade tumors than
were CW, deletion of PSHPL was not associated with
any pathological characteristics.
Discussion
AAW have the highest breast cancer mortality rates in the
United States with 32.4/100,000 deaths compared to CW
who have a mortality rate of 23.9/100,000 [12]. Thesegion of chromosome 7p and clinicopathological factors
CW
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A B EC D
Figure 2 PCR detection of deletion or insertion of PSPHL gene.
The forward primer that detects the deletion allele spans the deletion
breakpoint on chromosome 7p and the primer pair amplifies a 793 bp
fragment. The primers that detect the insertion product amplify a
208 bp fragment from exon 1 of PSPHL. Genotypes shown here are
A = del/del, B = del/del, C = ins/del, D = ins/ins, and E = ins/del. Primers
used are (all in 5′-3′ direction - insertion forward: AGGCTCCCTGGCTG
GC, insertion reverse: CAGGCTCAGGTGAGGCG, deletion forward:
AAGCCAGTGCGTCTACAGGTG, deletion reverse: GTGCCAGAAGAAC
CACACAGTC.
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such as access to health-care, however, within clinical
trials where treatment was standardized, pre- and post-
menopausal African American women demonstrated 40%
and 50% increased mortality rates, respectively [10].
Microarray analysis has identified a number of genes dif-
ferentially expressed in tumors from AAW compared to
CW, including SOS1, CRYBB2///CRYBB2P1 and PSPHL.
The significantly higher expression of PSPHL in tumors
from African Americans coupled with its putative role in
processes such as cellular proliferation may be con-
tributing to more aggressive tumor phenotypes and
less favorable outcomes in African Americans. More-
over, if altered expression of PSPHL does have a role
in tumorigenesis, it becomes a molecular target for the
development of new, tailored treatments for the African
American population.
Our data demonstrates that the deletion of 30 kb from
chromosome 7p11, including the promoter and the first
three of four exons of PSPHL, effectively eliminates
expression of PSPHL. The allele frequency of retention
of this region of chromosome 7p is high in AAW, and
only 6% of AAW were homozygous for the deletion and
thus did not express PSPHL. In contrast, the retention
allele frequency was only 21% in CW and 62% of Caucasian
cases expressed no PSPHL. These data thus provide a
functional explanation for expression differences across
individuals and between populations. Previous data from
our laboratory demonstrated that while within populations,
expression levels of PSPHL did not differ significantly be-
tween tumor and non-malignant stroma, between popula-
tions, PSPHL levels were significantly higher in both tumortissues as well as non-malignant stroma. In addition, higher
expression levels of PSPHL in non-malignant tissues from
AAW were not associated with higher rates of tumor
development [6]. Given the contralateral diagnosis and that
none of the other non-malignant patients have progressed
to more advanced diagnoses, it is not clear that increased
PSPHL is associated with tumorigenesis. In addition, the
absence of expression of PSPHL in patients homozygous
for the deletion on chromosome 7p was not associated
with unfavorable tumor characteristics or survival. In ad-
dition to the higher levels of PSPHL in a variety of tumor
types, the surrounding tumor stroma and non-malignant
breast tissues, significantly higher expression of PSPHL
was also detected in blood endothelial cells from healthy
African Americans compared to Caucasians [13]. Together
with our data demonstrating that the frequency of the
insertion allele did not differ significantly between African
American cases and controls, these data suggest that
PSPHL expression levels are not associated with breast
cancer etiology.
Conclusions
Differential expression of PSPHL provides an example of
how population stratification may confound identifica-
tion of genes associated with health care disparities.
Given the higher expression levels of PSPHL in breast and
prostate tumors from African Americans, a two-gene pre-
dictor including PSPHL and CRYBB2 has been proposed
to effectively distinguish between tumor epithelia from
African American and European Americans [7], however,
whether and how these genes play a role in tumor etiology
was not determined. Although PSPHL is expressed at
higher levels in breast (and other) tumors from African
Americans, it is also expressed at significantly higher
levels in non-tumor tissues as well as blood. In addition,
the frequency of the deletion variant which determines
expression levels of PSPHL is significantly higher in
Caucasians but does not differ between African American
cases and controls. Thus, differential expression of PSPHL
caused by retention of a 30 Kb region of 7p11 in indi-
viduals of African Ancestry suggests that this difference
represent population stratification, and does not contrib-
ute to cancer disparities.
Methods
Eligibility and enrollment
For inclusion in the Clinical Breast Care Project (CBCP),
all patients must have met the following eligibility criteria:
1) adult over the age of 18 years, 2) mentally competent
and willing to provide informed consent, and 3) pre-
senting to participating breast centers with evidence of
possible breast disease or for routine mammographic
screening. Tissue and blood samples were collected with
approval from the Walter Reed National Military Medical
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Board. All subjects enrolled in the CBCP voluntarily agreed
to participate and gave written informed consent. Clinical
information was collected for all CBCP samples using
questionnaires designed by and administered under the
auspices of the CBCP.
Deletion/insertion polymorphism detection and gene
expression analysis
Genomic DNA (AAW invasive = 199, AAW control = 360,
CW invasive = 589, CW controls = 364) was isolated from
blood clots using the Gentra Clotspin and Puregene DNA
purification kits (Qiagen., Valencia, CA). The del/ins poly-
morphism was assessed using the primer sets described in
[3], and the resulting PCR products run on 2% agarose gels
(Figure 2). Hardy-Weinberg equilibrium was determined
for each population using the OEGE- Online Encyclopedia
for Genetic Epidemiology studies Hardy-Weinberg equi-
librium calculator (http://www.oege.org/software/hwe-mr-
calc.shtml). RNA was isolated from tumor specimens
(n = 116) after laser microdissection as previously de-
scribed [6]. RNA was isolated from blood samples (n = 49)
collected in PAXgene Blood RNA tubes (Becton Dickin-
son, Franklin Lakes, NJ) and isolated using the PAXgene
Blood RNA Kit IVD (Qiagen, Valencia, CA) according to
manufacturer’s recommendations.
For qRT-PCR, RNA was reverse transcribed using
the High-Capacity cDNA Reverse Transcription kit
(Life Technologies, Grand Island, NY). qRT-PCR was
performed using TaqMan gene expression assay
Hs00863464_m1 (Life Technologies, Grand Island, NY).
Amplification was performed in duplicate using TaqMan
Universal PCR Master Mix (Life Technologies, Grand
Island, NY). GAPDH was used as the endogenous
control for normalization of all assays. Relative quan-
tification of gene expression levels was determined
using the Comparative Ct method [14].
Statistical analysis
Allele and genotype frequencies were compared be-
tween AAW with and without invasive breast cancer
and between AAW and CW with invasive breast cancer
by chi-square analysis using rxc Contingency Tables. For
qRT-PCR data, the medians of the 2-ΔΔCt values were
compared using a Mann–Whitney U test to determine if
the relative fold change was significantly different (two-
tailed) between genotypes. Significance was determined
using P < 0.05.
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